Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of RTA 1701 in Healthy Adults
NCT03579030Phase 1Completed
- Sponsor
- Biogen
- Start
- Jun 2018
- Primary completion
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of RTA 1701 in autoimmune diseases and Inflammatory Disorders (4 arms), sponsored by Biogen. Primary endpoint: Incidence of treatment-emergent adverse events at 3 weeks. Started Jun 2018; status: completed.
02
Drugs
RTA 1701
03
Conditions
autoimmune diseasesInflammatory Disorders
Beyond the preview
Go deeper on NCT03579030.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03579030.